Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $40.43 million. The enterprise value is $15.80 million.
Market Cap | 40.43M |
Enterprise Value | 15.80M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
Earnings Date | Aug 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.35 million shares outstanding. The number of shares has increased by 2.34% in one year.
Shares Outstanding | 5.35M |
Shares Change (YoY) | +2.34% |
Shares Change (QoQ) | +0.77% |
Owned by Insiders (%) | 2.91% |
Owned by Institutions (%) | 9.03% |
Float | 5.19M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 8.58 |
Forward PS | 22.58 |
PB Ratio | 1.69 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 3.35 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.99, with zero debt.
Current Ratio | 16.99 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.60% and return on invested capital (ROIC) is -43.29%.
Return on Equity (ROE) | -37.60% |
Return on Assets (ROA) | -34.60% |
Return on Capital (ROIC) | -43.29% |
Revenue Per Employee | $277,139 |
Profits Per Employee | -$527,543 |
Employee Count | 17 |
Asset Turnover | 0.18 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $755 in taxes.
Income Tax | 755 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.97% in the last 52 weeks. The beta is 1.17, so Lipocine's price volatility has been higher than the market average.
Beta (5Y) | 1.17 |
52-Week Price Change | +53.97% |
50-Day Moving Average | 6.58 |
200-Day Moving Average | 4.24 |
Relative Strength Index (RSI) | 49.53 |
Average Volume (20 Days) | 89,316 |
Short Selling Information
The latest short interest is 155,615, so 2.91% of the outstanding shares have been sold short.
Short Interest | 155,615 |
Short Previous Month | 156,146 |
Short % of Shares Out | 2.91% |
Short % of Float | 3.00% |
Short Ratio (days to cover) | 4.07 |
Income Statement
In the last 12 months, Lipocine had revenue of $4.71 million and -$8.97 million in losses. Loss per share was -$1.71.
Revenue | 4.71M |
Gross Profit | 4.71M |
Operating Income | -10.37M |
Pretax Income | -8.97M |
Net Income | -8.97M |
EBITDA | -8.94M |
EBIT | -8.97M |
Loss Per Share | -$1.71 |
Balance Sheet
The company has $24.63 million in cash and no debt, giving a net cash position of $24.63 million or $4.61 per share.
Cash & Cash Equivalents | 24.63M |
Total Debt | n/a |
Net Cash | 24.63M |
Net Cash Per Share | $4.61 |
Equity (Book Value) | 23.96M |
Book Value Per Share | 4.48 |
Working Capital | 23.83M |
Cash Flow
In the last 12 months, operating cash flow was -$5.53 million and capital expenditures -$9,167, giving a free cash flow of -$5.54 million.
Operating Cash Flow | -5.53M |
Capital Expenditures | -9,167 |
Free Cash Flow | -5.54M |
FCF Per Share | -$1.04 |
Margins
Gross margin is 100.00%, with operating and profit margins of -220.10% and -190.35%.
Gross Margin | 100.00% |
Operating Margin | -220.10% |
Pretax Margin | -190.34% |
Profit Margin | -190.35% |
EBITDA Margin | -189.65% |
EBIT Margin | -190.34% |
FCF Margin | -117.58% |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.34% |
Shareholder Yield | -2.34% |
Earnings Yield | -22.18% |
FCF Yield | -13.70% |
Analyst Forecast
The average price target for Lipocine is $33.00, which is 336.51% higher than the current price. The consensus rating is "Buy".
Price Target | $33.00 |
Price Target Difference | 336.51% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
Last Split Date | May 12, 2023 |
Split Type | Reverse |
Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of 5.63 and a Piotroski F-Score of 3.
Altman Z-Score | 5.63 |
Piotroski F-Score | 3 |